Minh Ho
he/him/his
Research Associate 2, MS - Bunick LabCards
About
Research
Publications
2024
Unveiling the secrets of vimentin filament architecture relevant to human disease
Lomakin I, Ho M, Bunick C. Unveiling the secrets of vimentin filament architecture relevant to human disease. Nature Structural & Molecular Biology 2024, 31: 849-851. PMID: 38684931, DOI: 10.1038/s41594-024-01301-x.Peer-Reviewed Original ResearchAltered skin microbiome, inflammation, and JAK/STAT signaling in Southeast Asian ichthyosis patients
Ho M, Nguyen H, Van Hoang M, Bui T, Vu B, Dinh T, Vo H, Blaydon D, Eldirany S, Bunick C, Bui C. Altered skin microbiome, inflammation, and JAK/STAT signaling in Southeast Asian ichthyosis patients. Human Genomics 2024, 18: 38. PMID: 38627868, PMCID: PMC11022333, DOI: 10.1186/s40246-024-00603-x.Peer-Reviewed Original ResearchConceptsSkin microbiomeCI patientsJAK/STAT-signaling pathwayRecurrent pathogenic variantsMeta-genomeCommensal microbiotaHereditary skin disordersJAK/STAT signalingIncreased production of inflammatory cytokinesIncreased susceptibility to infectionJAK/STAT-signalingPeripheral blood mononuclear cellsPathogenic variantsAge- and gender-matched controlsSkin barrier defectsHigher colonizationResultsThis case-control studyProduction of inflammatory cytokinesMicrobial populationsBlood mononuclear cellsImproving therapeutic managementEpidermal scalesCase-control studyMicrobiomeGender-matched controlsStructural Basis for p19 Targeting by Anti–IL-23 Biologics: Correlations with Short- and Long-Term Efficacy in Psoriasis
Daniele S, Eldirany S, Damiani G, Ho M, Bunick C. Structural Basis for p19 Targeting by Anti–IL-23 Biologics: Correlations with Short- and Long-Term Efficacy in Psoriasis. JID Innovations 2024, 4: 100261. PMID: 38445231, PMCID: PMC10914523, DOI: 10.1016/j.xjidi.2024.100261.Peer-Reviewed Original ResearchIL-23Clinical efficacyIL-23 inhibitors risankizumabSurface areaLong-term clinical efficacyMolecular propertiesIL-23 inhibitorsSolvent accessible surface areaHydrogen-deuterium exchangeIL-23 p19 subunitAccessible surface areaAssociated with short-Clinical efficacy scorePlaque psoriasisClinical responseP19 subunitCrystallographic experimentsPsoriasis pathogenesisReceptor epitopesInhibitor epitopesPsoriasisLinear regression analysisEfficacyTherapeutic classesBinding affinity
2023
831 The skin microbiome and inflammation of Southeast Asian patients with cutaneous ichthyosis
Bui B, Ho M, Bunick C. 831 The skin microbiome and inflammation of Southeast Asian patients with cutaneous ichthyosis. Journal Of Investigative Dermatology 2023, 143: s143. DOI: 10.1016/j.jid.2023.03.841.Peer-Reviewed Original Research
2022
Update of the keratin gene family: evolution, tissue-specific expression patterns, and relevance to clinical disorders
Ho M, Thompson B, Fisk JN, Nebert DW, Bruford EA, Vasiliou V, Bunick CG. Update of the keratin gene family: evolution, tissue-specific expression patterns, and relevance to clinical disorders. Human Genomics 2022, 16: 1. PMID: 34991727, PMCID: PMC8733776, DOI: 10.1186/s40246-021-00374-9.Peer-Reviewed Original ResearchConceptsTissue-specific expression patternsKeratin genesExpression patternsHuman disease-causing variantsType II keratin genesGenotype-Tissue Expression (GTEx) projectIntermediate filament genesKeratin gene familyEarly metazoan evolutionGene expression patternsAmphibian genomesZebrafish genomeAnimal genomesParalogous proteinsMetazoan evolutionGene expansionChromosome 17q21.2Gene familyFilament genesSpecies survivalDivergent functionsExpression projectChromosomal segmentsChr 11Chr 15
2020
Recent insight into intermediate filament structure
Eldirany SA, Lomakin IB, Ho M, Bunick CG. Recent insight into intermediate filament structure. Current Opinion In Cell Biology 2020, 68: 132-143. PMID: 33190098, PMCID: PMC7925366, DOI: 10.1016/j.ceb.2020.10.001.Peer-Reviewed Original ResearchConceptsIntermediate filamentsAssembly mechanismVariable N-terminalMultiple cellular processesCentral rod domainIntermediate filament structureCoil 1BCellular processesStudy of keratinsTail domainFilament assemblyRod domainC-terminalN-terminalElectrostatic surfacePathologic mutationsKey playersFilament structureRecent insightsComplex formationProteinHuman tissuesGlial fibrillary acidic proteinAcidic proteinDomainMolecular Modeling of Pathogenic Mutations in the Keratin 1B Domain
Hinbest AJ, Eldirany SA, Ho M, Bunick CG. Molecular Modeling of Pathogenic Mutations in the Keratin 1B Domain. International Journal Of Molecular Sciences 2020, 21: 6641. PMID: 32927888, PMCID: PMC7555247, DOI: 10.3390/ijms21186641.Peer-Reviewed Original ResearchStructural properties of target binding by profilaggrin A and B domains and other S100 fused-type calcium-binding proteins
Hinbest AJ, Kim SR, Eldirany SA, Lomakin IB, Watson J, Ho M, Bunick CG. Structural properties of target binding by profilaggrin A and B domains and other S100 fused-type calcium-binding proteins. Journal Of Dermatological Science 2020, 100: 39-49. PMID: 32893105, PMCID: PMC7752840, DOI: 10.1016/j.jdermsci.2020.08.009.Peer-Reviewed Original ResearchAmino Acid SequenceAnnexin A2Binding SitesCrystallography, X-RayFilaggrin ProteinsHumansHydrophobic and Hydrophilic InteractionsIntermediate Filament ProteinsIntermediate FilamentsKeratinocytesKeratinsMolecular Docking SimulationMutationProtein BindingProtein Conformation, alpha-HelicalProtein DomainsProtein PrecursorsRecombinant ProteinsS100 ProteinsCrystal Structure of Keratin 1/10(C401A) 2B Heterodimer Demonstrates a Proclivity for the C-Terminus of Helix 2B to Form Higher Order Molecular Contacts.
Lomakin IB, Hinbest AJ, Ho M, Eldirany SA, Bunick CG. Crystal Structure of Keratin 1/10(C401A) 2B Heterodimer Demonstrates a Proclivity for the C-Terminus of Helix 2B to Form Higher Order Molecular Contacts. The Yale Journal Of Biology And Medicine 2020, 93: 3-17. PMID: 32226330, PMCID: PMC7087056.Peer-Reviewed Original ResearchStructural Basis for How Biologic Medicines Bind their Targets in Psoriasis Therapy.
Eldirany SA, Ho M, Bunick CG. Structural Basis for How Biologic Medicines Bind their Targets in Psoriasis Therapy. The Yale Journal Of Biology And Medicine 2020, 93: 19-27. PMID: 32226331, PMCID: PMC7087057.Peer-Reviewed Original ResearchConceptsBiologic therapyTumor necrosis factor alphaFirst-line treatmentTreatment of psoriasisNecrosis factor alphaClinical responseInterleukin-17Interleukin-23Line treatmentPrescribing practicesPsoriasis therapyInflammatory disordersTreatment optionsTherapeutic decisionsClinical dataFactor alphaPatient safetyTherapySignificant differencesBiologic medicinesDrugsEpitope locationMolecular differencesTreatmentMedications